Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.
Neurizon Therapeutics Limited has commenced the manufacturing of the first registration batch of its lead drug candidate, NUZ-001, marking a significant milestone towards its commercialisation and regulatory submission to the FDA. This development, in partnership with Catalent, aims to support stability studies, regulatory submissions, and commercial readiness, enhancing Neurizon’s market access and long-term value creation. The company is preparing for a Phase 2/3 clinical trial in the HEALEY ALS Platform Trial, with a focus on accelerating approval pathways and biomarker-informed approaches to benefit patients, healthcare systems, and shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Their lead drug candidate, NUZ-001, is being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease. The company aims to accelerate access to effective ALS treatments and explore broader applications for NUZ-001 in neurodegenerative disorders.
Average Trading Volume: 347,041
Technical Sentiment Signal: Buy
Current Market Cap: A$76.31M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.